- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
David J. Farber
News 8 results
In the News · Source: Healthcare Brew
In the News · Source: Law360 Healthcare Authority
Recognition
June 12, 2024
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2024 Guide
In the News · Source: Verywell Health
July 14, 2023
David Farber discusses the FDA recently granting full approval to Leqembi, a drug to treat mild Alzheimer’s disease
Events 18 results
Webinar
February 13, 2025
Impact of the 2024 Election on Pharmaceutical, Biologics and Device Manufacturers
Conference
September 5, 2024
17th Annual King & Spalding Medical Device Summit
Speaking Engagement
March 12, 2024
Jeffrey Shapiro and David Farber to Speak at Fogarty Innovation
Conference
November 7, 2023
Pharmaceutical University 2023
Insights 36 results
Article · Source: Law360
September 17, 2024
CMS' New 'Breakthrough' Device Policy Shows Little Promise
Client Alert
September 4, 2024
Transitional Coverage for Emerging Technologies: CMS’s Latest, But Not Necessarily Greatest, Coverage with Evidence Approach
Client Alert
Client Alert
October 3, 2023
FDA's Latest Salvo in the LDT Wars